{
  "image_filename": "table_p11_det_10_013.png",
  "image_path": "Liu_et_al.__2024_/extracted/figures/table_p11_det_10_013.png",
  "image_type": "Table",
  "page_number": 11,
  "block_id": "det_10_013",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "Table showing demographic characteristics (age, age group, sex, race/ethnicity, site, and prior influenza vaccination history) for four study groups (n=122, n=120, n=283, n=198) from a comparative immunogenicity trial. The table only presents baseline participant demographics and does not include any immunogenicity or cross-protection data, and thus does not support the claim Note: Only demographic data is visible; no antibody response or efficacy outcomes are shown",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table showing demographic characteristics (age, age group, sex, race/ethnicity, site, and prior influenza vaccination history) for four study groups (n=122, n=120, n=283, n=198) from a comparative immunogenicity trial.",
    "evidence_found": null,
    "reasoning": "The table only presents baseline participant demographics and does not include any immunogenicity or cross-protection data, and thus does not support the claim",
    "confidence_notes": "Only demographic data is visible; no antibody response or efficacy outcomes are shown"
  }
}